GLP-1 weight loss drugs include potential immune benefits in gut tissue

HIV i-Base news story

CROI 2026 included an oral plenary talk on the use of GLP-1 receptor agonists in people living with HIV, plus an additional oral presentation and seven posters.

These covered the short-term impact of GLP-1s in a real-world setting, potential benefits on reducing smoking, cardiovascular risk, depression, and liver fibrosis, with an oral abstract on the potential to perhaps reverse the gut damage that occurs in very early HIV infection and that persists despite effective ART.

Read the full news story here.View all HIV i-Base reports from CROI 2026